Potential rules of anesthetic gases on glioma

Xiao Chen*, Yi-Guang Mao*, Zheng-Quan Yu*, Jiang Wu*, Gang Chen
Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China

*Correspondence to: Zheng-Quan Yu, zhengquan_yu@126.com; Jiang Wu, szjiangwu@163.com.
#These authors contributed equally to this work.
ocrid: 0000-0002-8336-0436 (Zheng-Quan Yu)

Abstract

Glioma is one of the most frequent primary brain tumors. Currently, the most common therapeutic strategy for patients with glioma is surgical resection combined with radiotherapy or/and adjuvant chemotherapy. However, due to the metastatic and invasive nature of glioma cells, the recurrence rate is high, resulting in poor prognosis. In recent years, gas therapy has become an emerging treatment. Studies have shown that the proliferation, metastasis and invasiveness of glioma cells exposed to anesthetic gases are obviously inhibited. Therefore, anesthetic gas may play a special therapeutic role in gliomas. In this review, we aim to collect existing research and summarize the rules of using anesthetic gases on glioma, providing potential strategies for further clinical treatment.

Key words: anesthetic gases; glioma; invasion; isoflurane; metastasis; proliferation; sevoflurane

doi: 10.4103/2045-9912.279984
How to cite this article: Chen X, Mao YG, Yu ZQ, Wu J, Chen G. Potential rules of anesthetic gases on glioma. Med Gas Res. 2020;10(1):50-53.

INTRODUCTION

Tumors derived from neuroepithelial cell are collectively referred to glioma, which account for 50% to 60% of the primary central nervous system tumors and is the most common intracranial malignancies.1 In terms of current treatment methods, surgical treatment is the primary treatment for patients with glioma. Although most postoperative patients receive follow-up radiotherapy and chemotherapy, the recurrence rate is still high and the prognosis is poor.2,3

At present, gas gradually shows its enormous therapeutic potential in nervous system,4,5 cardiovascular diseases6 and cancers.7 Anesthetic gases are administered as the primary therapy for sedation in the perioperative setting and critical care. Compared with current intravenous sedation agents, anesthetic gases-induced sedation may provide superior awakening and extubation times. Although they have been widely used, the mechanism by which they induce and maintain anesthesia has not been clarified. On the one hand, they can reduce presynaptic excitation and neurotransmitter release through inhibition of sodium (Na+) and several isoforms of calcium (Ca2+) voltage-gated channels; on the other hand, they also reduce neurotransmitter activity in the postsynaptic membrane by γ-aminobutyric acid, glycine, nicotinic acetylcholine, serotonin type 3, glutamate, N-methyl-D-aspartate, and α-amin-3-hydroxy-5-methyl-4-isooazolepropionic acid receptors.8,9

Numerous studies have found that anesthetic gases may influence tumor recurrence, metastasis, and long-term survival.10,11 Due to the high degree of malignancy and recurrence rate of glioma, the application of anesthetics in glioma has also received more and more attention. In this article, we intend to summarize the previous studies and explain the effects of anesthetic gases on glioma, providing evidence for future gas therapy.

At present, sevoflurane and isoflurane are the two commonly used anesthetic gases in clinic. Due to research and space limitations, we only discuss the above two anesthetic gases in this review.

SEARCH STRATEGY

PubMed database was searched up to May 2019. The term “anesthetics” (including anesthetic gases, sevoflurane, or isoflurane) as a medical subject heading (MeSH) and key word, was combined with the term “glioma” as a medical subject heading (MeSH) and key word.

ANESTHETICS GASES

Sevoflurane

Sevoflurane, a volatile anesthetic, is used to induce and maintain general anesthesia for outpatients and inpatients.12 It has stable physical properties, rapid induction and minimal inhibitory effects on circulation. After being applied in more and more research, its special effects on cancer and tumors are discovered. For instance, it is well known that sevoflurane can play a protection for the lungs during surgery, and can also reduce the metastasis of cancer cells caused by surgery by promoting apoptosis of A549 cells (the human pulmonary adenocarcinoma cell line).10 Fan et al.13 have found that sevoflurane can reduce the metastasis and invasion of colorectal cancer cells.

Isoflurane

Isoflurane, a structural isomer to enfurane, is also a commonly used volatile anesthetic. But unlike enfurane, isoflurane carries a strong pungent odor that makes it difficult to use for inhalational induction of general anesthesia.14 In addition to inducing anesthesia, isoflurane also shows the function of protecting organs from damage in hypoxic ischemic brain injury and myocardial ischemia-reperfusion injury.15,16 The study has found that isoflurane can inhibit the expression of phosphati-
dyinositol 3-kinase and protein kinase B (AKT) and reduce the activity of nuclear factor kappa-B to inhibit the metastasis and invasion of liver cancer cells, and also can induce caspase 3 activation in cancer cells to induce apoptosis.17 In addition, it also has a role in soft nest cancer18 and lupus nephritis.19

**Experimental Studies of Anesthetics Gases in Glioma**

It is well known that a treatment must be verified by large number of basic experiments before being applied to clinic. However, different studies may show different results. We collect several experiments related to gliomas and anesthetic gases and summarize the outcomes in this article (Table 1). Yi et al.20 found that after sevoflurane treatment, the migration and invasion abilities of glioma cells were significantly reduced,17 with increasing concentration. In another study, sevoflurane was found to inhibit the matrix metalloproteinase-2 (MMP-2) activity in glioma cells and reduced their metastasis and invasion.21 Meuth et al.22 and O’Leary et al.23 found that isoflurane could promote the death of glioma cells. By comparing the effects of isoflurane, enflurane and sevoflurane on glioma cells, isoflurane is found to have the best anti-proliferative effect on C6 glioma, while sevoflurane has the worst. In addition to inhibition, some studies have the opposite conclusion. Shi et al.24 found that sevoflurane promoted the production of hypoxia-inducible factors in a concentration-dependent manner and up-regulated the level of p-AKT, thereby promoting the proliferation of glioma stem cells. The same was true for isoflurane that exposure to isoflurane could promote the proliferation, survival and migration distance of human glioblastoma stem cells.25 These conflicting results may be attributable to the heterogeneity of responses to the anesthesics gases depending on cell type, concentration, duration of exposure, or all.

**Clinical Applications**

Currently, most studies are limited to cellular levels. Although rats were used in one study, the anesthetic gas was not directly applied to rats with glioma.26 Instead, the glioma cells were pretreated with anesthetic gas and injected into the right striatum to quantify the migratory potential capacity of cells in vivo. The results showed that the migration ability of glioma stem cells pre-exposed to 1.2% isoflurane was significantly enhanced. In addition to ethical reasons, one important reason is that the research is not yet mature. First, there are many types of gliomas, and the characteristics of each are different. Therefore, different anesthetics gases may have different effects on different types of tumors. Secondly, the gas concentration, exposure time and adverse reactions are difficult to control. Therefore, further relevant research is needed.

**Mechanisms of Anesthetics Gases in Glioma**

Metastasis and invasion are main causes of poor prognosis and relapse in patients suffering from glioma, and are receiving more and more attention in scientific and clinical research.26,27 Anesthetics gases show an effective inhibitory effect on the survival, metastasis and invasion of glioma cells. However, due to the complexity of the processes, the molecular mechanisms have not been fully elucidated.

Micro-RNAs (miRNAs) are a class of small noncoding RNAs with 21–25 nucleotides, which regulate the target gene expression by repressing translation or regulating mRNA degradation via binding to the 3’ untranslated region of their target genes.28 They have important impacts on the progression of proliferation, migration and invasion.29-31 A large number of studies have found that the effect of anesthetic gases on cancer cells is related to miRNAs.13,32 And the same is true for gliomas. MiR-637 is considered to be an inhibitor of hepatocellular carcinoma and pancreatic cancer.33 AKT is a target protein of miR-637, and AKT phosphorylation may promote tumor development and progression.34 Compared to normal brain tissue, the level of miR-637 in glioma cells is low, and the combination of miR-637 and AKT is reduced in gliomas.35 After treatment with sevoflurane, miR-637 is significantly up-regulated, and the expression and activity of AKT are also inhibited.26 At the same time, metastasis and invasion of glioma cells are also inhibited. Emerging evidence has suggested that the pathogenesis of anesthetic gases on cancer cells is related

| Table 1: The effects of anesthetic gases in glioma |
|-------------------------------|-------------|---------|---------------------|----------|----------------|
| Study Year Cells lines Gases Dose Duration Main results |
| Yi et al. 2016 Human glioma cell line U251 Sevoflurane 1.7%, 3.4%, 5.1% 6 h The U251 cells treated with sevoflurane exhibited a significantly decreased migratory and invasive ability in a dose-dependent manner. |
| Hurmath et al. 2016 Human glioma cells U87MG Sevoflurane 2.50% 1.5 h Sevoflurane could inhibit the migration and matrix metalloproteinase-2 activity in glioma cells. |
| Zhu et al. 2016 Human glioblastoma cell line U251 Isoflurane 0.6%, 1.2%, 2.4% 3–12 h Isoflurane could increase glioma cells proliferation and decrease their apoptosis rate in a dose-dependent manner. |
| Shi et al. 2015 Human primary glioma stem cells Sevoflurane 1–6% 0–6 h Sevoflurane promoted the growth of glioma stem cells and increased hypoxia-inducible factors and p-protein kinase B expression in a dose-dependent manner. |
| Meuth et al. 2008 Human glioma cell line Isoflurane 1.00% Unclear Isoflurane reduced the survival rate of glioma cells. |
| O’Leary et al. 2000 C6 glioma cells Isoflurane, enflurane, sevoflurane 0–2.0 mM 48 h All three anesthetic gases could inhibit the proliferation of glioma cells. |
to a group of miRNAs, not individual. Therefore, there may be more miRNAs involved.

Besides AKT, considerable evidence suggests that MMP-2 plays an important role in the metastasis and invasion of glioma cells. In addition, MMP-2 is involved in the degradation of the blood-brain barrier, which will cause hematogenous metastases of cancer cells to form new cancer foci that cannot be distinguished by naked eye. Therefore, the high expression of MMP-2 is an indication of poor prognosis. Moreover, there is also a close relationship between MMP-2 and AKT in gliomas. Many substances can upregulate the expressions of MMP-2 through AKT signaling pathway in gliomas. However, whether sevoflurane can affect the expression of MMP-2 through the AKT pathway needs further verification.

In addition to targeting proteins, anesthetic gases can also act on glioma cells by inhibiting the channel. It is well known that ion channels are also involved in the migration and proliferation of tumor cells. So they have been identified as promising therapeutic targets of brain tumor. One of the most important glioma-related channels is Ca2+-activated K+ channels, being overexpressed in glioma patients. Currently, there are some drugs targeting this channel for the treatment of gliomas. For example, Oxaliplatin, a third-generation organoplatinum, can suppress the amplitude of glioma cell K+ currents by inhibiting Ca2+-activated K+ channels, thereby affecting cell activity.

The above mechanism is mainly to explain the beneficial aspects of anesthetic gases, while one study has found that anesthetic gas can stimulate the proliferation of glial stem cells by up-regulating the expression of AKT. And in addition to glioma, the effect on other tumors is not consistent. Therefore, the mechanism of anesthetic gases on glioma requires more types, more rigorous and more detailed research.

CONCLUSION

Although anesthetic gases have been used for decades, most of them are used as anesthesia inducers. So far, most of the experiments on gliomas are limited to the cell stage, and the application to the living body has not been reported. Anesthetics may have side effects on brain function due to its toxicity. For example, it may cause apoptosis of normal nerve cells and affect the learning and behavior of humans and animals. Therefore, there are still great challenges in the application of living organisms. As far as current research is concerned, different anesthetic gases have different effects on different types of glioma cells.

Moreover, there is also no consensus on the optimal concentration of the application. Clinically, the choice of anesthetic dose is based on the minimum alveolar concentration. It is defined as the concentration of inhaled anesthetic within the alveoli at which 50% of people do not move in response to a surgical stimulus. Many variables can alter minimum alveolar concentration, such as age, temperature and pregnancy. Therefore, the minimum alveolar concentration should be monitored and adjusted to the appropriate range during sedation. Since most of the current studies are still limited to the cellular level rather than the living body, a fixed concentration is given, which leads to differences in the dose of intervention and application in clinic.

Therefore, whether in vitro or in vivo, research will continue. Through the above introduction, anesthetic gas may become an emerging treatment of glioma. Although there are still many questions and problems at present, one day it will come to a conclusion.

REFERENCES

1. Chen X, Yang F, Zhang T, et al. MiR-9 promotes tumorigenesis and angiogenesis and is activated by MYC and OCT4 in human glioma. J Exp Clin Cancer Res. 2019;38:99-99.
2. Wang PG, Li YT, Pan Y, et al. Lower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy. J Neurooncol. 2019;141:71-81.
3. Xue L, Lu B, Gao B, et al. NLRP3 promotes glioma cell proliferation and invasion via the interleukin-1β/NF-kB p65 signals. Oncol Res. 2019;27:557-564.
4. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella AMG. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci. 2007;8:766-775.
5. Zhang X, Bian JS. Hydrogen sulfide: a neuromodulator and neutrophil modulator in the central nervous system. ACS Chem Neurosci. 2014;5:876-883.
6. Farah C, Michel LY, Balligand JL. Nitric oxide signalling in cardiovascular health and disease. Nat Rev Cardiol. 2018;15:292-316.
7. He Q. Precision gas therapy using intelligent nanomedicine. Biomater Sci. 2017;5:2226-2230.
8. Jerath A, Parotto M, Wasowicz M, Ferguson ND. Volatile anaesthetics: is a new player emerging in critical care sedation? Am J Respir Crit Care Med. 2016;193:1202-1212.
9. Edginton TL, Maani CV. Sevoflurane. StatPearls. Treasure Island: StatPearls Publishing; 2019.
10. Wang L, Wang T, Gu JQ, Su HB. Volatile anesthetic sevoflurane suppresses lung cancer cells and miRNA interference in lung cancer cells. Onco Targets Ther. 2018;11:5689-5693.
11. Jose C, Hebert-Chatelain E, Dias Amoedo N, et al. Redox mechanism of levobupivacaine cytostatic effect on human prostate cancer cells. Redox Biol. 2018;18:33-42.
12. Brion JD, Varughese S, Ahmed R, Bein B. A clinical review of inhalation anesthesia with sevoflurane: from early research to emerging topics. J Anesth. 2017;31:764-778.
13. Fan L, Wu Y, Wang J, He J, Han X. Sevoflurane inhibits the migration and invasion of colorectal cancer cells through regulating ERK/MMP-9 pathway by up-regulating miR-203. Eur J Pharmacol. 2019;850:43-52.

14. Hawkley TF, Maani CV. Isoflurane. StatPearls. Treasure Island: StatPearls Publishing. 2019.

15. Burchell SR, Dixon BJ, Tang J, Zhang JH. Isoflurane provides neuroprotection in neonatal hypoxic ischemic brain injury. J Investig Med. 2013;61:1078-1083.

16. Lang XE, Wang X, Jin JH. Mechanisms of cardioprotection by isoflurane against 1/IR injury. Front Biosci (Landmark Ed). 2013;18:387-393.

17. Hu J, Hu J, Jiao H, Li Q. Anesthetic effects of isoflurane and the molecular mechanism underlying isoflurane-inhibited aggressiveness of hepatic carcinoma. Mol Med Rep. 2018;18:184-192.

18. Guo NL, Zhang JX, Wu JP, Xu YH. Isoflurane promotes glucose metabolism through up-regulation of miR-21 and suppresses mitochondrial oxidative phosphorylation in ovarian cancer cells. Biosci Rep. 2017;37:BSR20170818.

19. Yuan Y, Liu Z. Isoflurane attenuates murine lupus nephritis by inhibiting NLRP3 inflammasome activation. Int J Clin Exp Med. 2015;8:17730-17738.

20. Yi W, Li D, Guo Y, Zhang Y, Huang B, Li X. Sevoflurane inhibits proliferation and invasion of glioma cells by upregulating microRNA-637. Int J Mol Sci. 2016;18:1857-1863.

21. Hurmath FK, Mittal M, Ramaswamy P, Umamaheswara Rao GS, Dalavakodihalli Nanjaiah N. Isoflurane and thiopental preconditioning attenuates the migration and activity of MMP-2 in U87MG glioma cells. Neurochem Int. 2016;94:32-38.

22. Meuth SG, Herrmann AM, Ip CW, et al. The two-pore domain potassium channel TASK3 functionally impacts glioma cell death. J Neurooncol. 2008;87:263-270.

23. O'Leary G, Bacon CL, Odumeru O, et al. Antiproliferative actions of inhalational anesthetics: comparisons to the valproate teratogen. J Exp Clin Cancer Res. 2018;37:65.

24. Shi QY, Zhang SJ, Liu L, et al. Sevoflurane promotes the expansion of glioma stem cells through activation of hypoxia-inducible factors in vitro. Br J Anaesth. 2015;114:825-830.

25. Zhu M, Li M, Zhou Y, et al. Isoflurane enhances the malignant potential of glioblastoma stem cells by promoting their viability, mobility in vitro and migratory capacity in vivo. Br J Anaesth. 2016;116:870-877.

26. Ma B, Zhang L, Zou Y, et al. Reciprocal regulation of integrin β4 and KLF4 promotes gliomagenesis through maintaining cancer stem cell traits. J Exp Clin Cancer Res. 2019;38:23-23.

27. Bian EB, Chen EF, Xu YD, et al. Exosomal IncRNA-ATB activates astrocytes that promote glioma cell invasion. Int J Oncol. 2019;54:713-721.

28. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350-355.

29. Wang Z, Tong D, Han C, et al. Blockade of miR-3614 maturation by IGFBP3 increases TRIM25 expression and promotes breast cancer cell proliferation. EBioMedicine. 2019;41:357-369.

30. Zhanh M, Zhao S, Jiang Z, et al. MALAT1 sponges miR-106b-5p to promote the invasion and metastasis of colorectal cancer via SLAIN2 enhanced microtubules mobility. EBioMedicine. 2019;41:286-298.

31. Sullivan TB, Robert LC, Teebagy PA, et al. Spatiotemporal microRNA profile in peripheral nerve regeneration: miR-138 targets vimentin and inhibits Schwann cell migration and proliferation. Neural Regen Res. 2018;13:1253-1262.

32. Liu J, Yang L, Guo X, et al. Sevoflurane suppresses proliferation by upregulating microRNA-203 in breast cancer cells. Mol Med Rep. 2018;18:455-460.

33. Xu RL, He W, Tang J, et al. Primate-specific miRNA-637 inhibited tumorigenesis in human pancreatic ductal adenocarcinoma cells by suppressing Akt1 expression. Exp Cell Res. 2018;363:310-314.

34. Xie L, Dai H, Li M, et al. MARCH1 encourages tumour progression of hepatocellular carcinoma via regulation of PI3K-akt-β-catenin pathways. J Cell Mol Med. 2019;23:3386-3401.

35. Que T, Song Y, Liu Z, et al. Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth, migration and invasion via direct targeting Akt1. Oncogene. 2015;34:4952-4963.

36. Chen G, Yue Y, Qin J, Xiao X, Ren Q, Xiao B. Plumbagin suppresses the migration and invasion of glioma cells via downregulation of MMP-2 expression and inaction of PI3K/Akt signaling pathway in vitro. J Pharmacol Sci. 2017;134:59-67.

37. Zhang H, Ma Y, Wang H, Xu L, Yu Y. MMP-2 expression and correlation with pathology and MRI of glioma. Oncol Lett. 2019;17:1826-1832.

38. By I, Li H, Yi D, et al. Cordycepin augments the chemosensitivity of human glioma cells to temozolomide by activating AMPK and inhibiting the AKT signaling pathway. Mol Pharm. 2018;15:4912-4925.

39. Liu M, Wang J, Huang B, Chen A, Li X. Oleuropein inhibits the proliferation and invasion of glioma cells via suppression of the AKT signaling pathway. Oncol Rep. 2016;36:2009-2016.

40. Tas PW, Kress HG, Koschel K. Volatile anesthetics inhibit the ion flux through Ca2+-activated K+ channels of rat glioma C6 cells. Biochim Biophys Acta. 1989;983:264-268.

41. Breuer EK, Fukushima-Lopes D, Dalheim A, et al. Potassium channel activity controls breast cancer metastasis by affecting β-catenin signaling. Cell Death Dis. 2019;10:180.

42. Turner KL, Honasoge A, Robert SM, McFerrin MM, Sontheimer H. A proinvasive role for the Ca2+-activated K+ channels on glioma cells in vivo. J Neurooncol. 2009;90:407-415.

43. Mohr CJ, Steudel FA, Gross D, et al. Cancer-associated intermediate conductance Ca2+-activated K+ channel KCa3.1 in malignant glioma. Glia. 2014;62:971-981.

44. Wang R, Zhang Z, Kumar M, Xu G, Zhang M. Neuroprotective potential of ketamine prevents developing brain structure impairment and alteration of neurocognitive function induced via isoflurane through the PI3K/AKT/GSK-3β pathway. Drug Des Devel Ther. 2019;13:501-512.

45. Hoffmann U, Sheng H, Ayata C, Warner DS. Anesthesia in experimental stroke research. Transl Stroke Res. 2016;7:358-367.

46. Duris K, Lipkova J, Spilchal Z, Madarasova T, Jurajda M. Early inflammatory response in the brain and anesthesia recovery time evaluation after experimental subarachnoid hemorrhage. Transl Stroke Res. 2018. doi: 10.1007/s12975-018-0641-z.

47. Liu X, Dingley J, Elstad M, Scull-Brown E, Steen PA, Thoresen M. Minimum alveolar concentration (MAC) for sevoflurane and xenon at normothermia and hypothermia in newborn pigs. Acta Anaesthesiol Scand. 2013;57:646-653.

48. Ni K, Cooter M, Gupta DK, et al. Paradox of age: older patients receive higher age-adjusted minimum alveolar concentration fraction of volatile anaesthetics yet display higher bispectral index values. Br J Anaesth. 2019;123:288-297.

49. Lee J, Lee J, Ko S. The relationship between serum progesterone concentration and anaesthetic and analgesic requirements: a prospective observational study of parturients undergoing cesarean delivery. Anesth Analg. 2014;119:901-905.

Received: August 8, 2019
Reviewed: August 12, 2019
Accepted: September 12, 2019